Respiratory Syncytial Virus Antibodies, Vaccines & Antivirals 2017; New Report Launched
This Competitive Intelligence Report about RSV Antibodies, Vaccines & Antivirals provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies, small molecules, protein and peptide therapeutics against infection caused by respiratory syncytial virus (RSV) as of March 2017.
View full press release